Drug Trials Snapshots: BIMZELX

BIMZELX is an anti-interleukin (IL)-17A and IL-17F monoclonal antibody that is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Source: FDA Center for Drug Evaluation and Research - What's New - February 15, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news